[期刊]
  • 《Future oncology》 2020年16卷30期

摘要 : FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has dem... 展开

相关作者
相关关键词